Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. - Wikidata - awgldk - TriplyDB

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.

http://www.wikidata.org/entity/Q33561227

about

Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.Chronic myeloid leukemia: mechanisms of resistance and treatment.Management of imatinib-resistant patients with chronic myeloid leukemia.Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML).Therapy of chronic myeloid leukemia: twilight of the imatinib era?Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.Current status of agents active against the T315I chronic myeloid leukemia phenotype.Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?Predicting the response of CML patients to tyrosine kinase inhibitor therapy.Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.Selection of therapy: rational decisions based on molecular events.Treatment options for chronic myeloid leukemia.Targeting VEGF in lung cancer.OCT1 and imatinib transport in CML: is it clinically relevant?Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversity.PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells.A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance.hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.[STAT5, a new therapeutic target against the relapse of chronic myelogenous leukemia?].Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.OCT-1 as a determinant of response to antileukemic treatment.

P2860

Q26741009-86F76E1E-96A9-4762-A8ED-3B6CE739EE4F Q26781539-C3CB02C9-EF6E-4CCD-ACB5-80C693A62EB3 Q26799458-E49F3ACC-8459-4E4F-A4BD-F1E2FDE5CB8C Q28545195-128FC70C-419F-4EB6-9D55-A247057B2386 Q33878636-4AFDDBC6-4466-4837-8DE0-6F2A51076E1B Q34525644-E577DC8E-1CA3-47A0-A8D3-471170D82BF3 Q35171271-D0A0743B-1D9C-49CC-B44E-FE0A11995782 Q35595795-222B0F46-7B10-4840-94EB-BF0CFF0EDF4F Q36776423-BD6529CB-4FC7-4743-A6A5-AB6069965049 Q37377316-1C5CA5D8-F6B7-4722-9D1E-C0E89E7675CA Q37490214-C50FC29C-F4A7-47C2-AF4C-8F31D3AA0B97 Q37593435-5AC53C98-32DB-4075-92CC-71D2A97C9D87 Q37810070-487FCAA7-80B7-47FA-8D91-DB992C342AA7 Q37836938-C617D357-21A4-48C6-8E84-7AA8A14BAB84 Q37847179-481F2DF1-65E5-4293-9E9C-97D5597E6E67 Q37853578-83381CBB-4749-4EA2-B5EF-77D4B5D20665 Q37859303-9C8BEE51-03C4-43D8-8D6E-90450BA7127B Q37888714-E9C77FC7-EF48-445C-8B1E-6F3C6F56B734 Q37952910-AB895D71-90F4-44D7-9259-690B50A30761 Q37994805-45698FC4-8A91-49C1-9BE4-BB5197CD40ED Q37996080-1CE996DA-FD38-4FDF-938B-C15613D1D23F Q38540022-C761CC5C-2680-44F4-B9B7-D8E193C8F8B5 Q38685803-92B11751-CE5D-44D1-B48B-57E62027A295 Q39640517-4E6D8B82-7598-4A8A-9FCC-27EC34EE07E0 Q39692439-138595A2-60D7-426D-ADFB-C8FBCF2A5ABA Q41007575-9F40D44F-CE45-4E22-8502-0396C92C8850 Q42110946-088A5B0C-D5BA-4214-A92D-395B66922857 Q42929915-1073E2C9-4EC7-4977-8DE2-731C2E713809 Q42938924-BA8D53BB-602B-445D-9C60-4CEEE672E596 Q43072797-DBB0F490-E9F5-4048-8066-6996DAD0A7DA Q44161665-332D5EEB-E302-4D52-88EB-4CDF70F01044 Q46450278-7BAD05F3-2339-4DDF-A605-E0F96B86BEE0 Q46788822-7C53786C-3697-4A7F-9C00-A0056B65913D Q47117554-BC58C519-D02C-45CC-8D76-594B26A5DB11 Q53017093-789AE680-897F-4DBE-8679-84F3C95D3A67 Q54240000-843C2010-71E2-44EA-819D-CCC270FDD11C Q54610682-EEA162FB-5B0C-4725-B887-618A752ACB13

P2860

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.

http://www.wikidata.org/entity/Q33561227

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Predictors of primary imatinib ...... secondary imatinib resistance.

@ast

Predictors of primary imatinib ...... secondary imatinib resistance.

@en

Predictors of primary imatinib ...... secondary imatinib resistance.

@nl

type

label

Predictors of primary imatinib ...... secondary imatinib resistance.

@ast

Predictors of primary imatinib ...... secondary imatinib resistance.

@en

Predictors of primary imatinib ...... secondary imatinib resistance.

@nl

prefLabel

Predictors of primary imatinib ...... secondary imatinib resistance.

@ast

Predictors of primary imatinib ...... secondary imatinib resistance.

@en

Predictors of primary imatinib ...... secondary imatinib resistance.

@nl

P1433

Q33561227-A9517F0D-04C2-4CBE-B5BA-9480FEC45E55

P1476

Q33561227-184D72EF-6DCE-4527-BA1B-40EB84F021E6

P2093

Q33561227-31DE9E53-3242-4118-90AE-023F780E587E

Q33561227-52CB962F-BBB8-43E1-832C-6C32170B2280

Q33561227-804F9F98-37C1-4CCD-AFF3-E22437FDB2D5

Q33561227-81755F3C-3AF3-4880-BFE7-9867642DBADA

Q33561227-F97F2C83-A113-4531-AA94-C2423746DA64

P2860

Q33561227-068EC91E-6637-4798-AEC0-C8E901BE1AC2

Q33561227-0BB9478B-27ED-4E78-871F-F6DF4CB4A912

Q33561227-19C8DBA3-0DC3-4417-8D33-AA6BB5432E93

Q33561227-19F787CC-859F-4009-8379-02108970E875

Q33561227-1ACD653A-95D3-4CBC-8662-D0D40FA62D7B

Q33561227-2934B481-A72C-465E-A7D9-AE67A1B44989

Q33561227-2E795021-C1A7-4440-8076-63422A9828EA

Q33561227-2F13BEF7-FBDD-47DB-BE19-28DA5F744EAF

Q33561227-3E9B20F6-C36E-4DAD-A677-B36E7C0F8940

Q33561227-4421DC3B-89AC-4709-BC92-075765B638EF

P304

Q33561227-E9A8FCF9-BD46-4F47-96D4-4408DBC0DEA6

P31

Q33561227-15B71FD1-3267-4143-9D0F-B257C3468CF4

P356

Q33561227-D343740D-1682-4A20-B40C-E9D6C3662A20

P407

Q33561227-91A625D7-0F9E-495D-881A-57F2C415D303

P433

Q33561227-B4612FEE-B087-4B85-9319-7E502339FFD8

P478

Q33561227-3E34F58A-F77B-4AEC-8EFC-5E3A8286B7C0

P50

Q33561227-557CE836-6908-4434-81D3-7DECFFE4EFB8

Q33561227-565C2AE0-A564-4179-B3D1-5D4FC55D61D6

Q33561227-7C4D478B-ACDF-4355-B3D8-3DD54984F2B4

P577

Q33561227-F94A41B0-845B-4864-9A2E-A7BA9931C33D

P698

Q33561227-2381C28A-27EB-4317-8DE7-1C0C358D5780

P921

Q33561227-CE0C0AC8-3E20-4BB5-9048-5F9A1220BBD0

P932

Q33561227-113F81AE-29FD-4EC3-83EC-F67321760442

P356

JCO.2008.19.4076

P1433

Journal of Clinical Oncology

P1476

Predictors of primary imatinib ...... secondary imatinib resistance.

@en

P2093

Dan Jones

http://www.w3.org/2001/XMLSchema#string

Hui Yao

http://www.w3.org/2001/XMLSchema#string

Li Zhang

http://www.w3.org/2001/XMLSchema#string

Neelima G Reddy

http://www.w3.org/2001/XMLSchema#string

Wenyong W Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data.

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.

Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.

Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia.

P304

3642-3649

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.19.4076

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

P577

2009-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19506164

http://www.w3.org/2001/XMLSchema#string

P921

P932

2799062

http://www.w3.org/2001/XMLSchema#string